130 related articles for article (PubMed ID: 15257382)
1. [Autoimmune functional disorders of the thyroid during interferon-beta-1b treatment in patients with multiple sclerosis. Case report and literature review].
Lange-Asschenfeldt C; Boor S; Kahaly GJ; Thömke F
Nervenarzt; 2004 Jun; 75(6):589-94. PubMed ID: 15257382
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves' disease.
Rotondi M; Mazziotti G; Biondi B; Manganella G; Del Buono AD; Montella P; di Cristofaro M; Di Iorio G; Amato G; Carella C
J Endocrinol Invest; 2000 May; 23(5):321-4. PubMed ID: 10882151
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
Schwid SR; Goodman AD; Mattson DH
Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis, interferon beta and clinical thyroid dysfunction.
Kreisler A; de Seze J; Stojkovic T; Delisse B; Combelles M; Vérier A; Hautecoeur P; Vermersch P;
Acta Neurol Scand; 2003 Feb; 107(2):154-7. PubMed ID: 12580868
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis.
Rotondi M; Oliviero A; Profice P; Mone CM; Biondi B; Del Buono A; Mazziotti G; Sinisi AM; Bellastella A; Carella C
J Endocrinol Invest; 1998 Dec; 21(11):748-52. PubMed ID: 9972674
[TBL] [Abstract][Full Text] [Related]
7. [Secondary progressive multiple sclerosis in childhood--interferon beta 1b treatment].
Higurashi N; Hamano S; Eto Y
No To Hattatsu; 2006 May; 38(3):209-13. PubMed ID: 16715936
[TBL] [Abstract][Full Text] [Related]
8. Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful?
Monzani F; Caraccio N; Casolaro A; Lombardo F; Moscato G; Murri L; Ferrannini E; Meucci G
Neurology; 2000 Aug; 55(4):549-52. PubMed ID: 10953190
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune events during interferon beta-1b treatment for multiple sclerosis.
Durelli L; Ferrero B; Oggero A; Verdun E; Bongioanni MR; Gentile E; Isoardo GL; Ricci A; Rota E; Bergamasco B; Durazzo M; Saracco G; Biava MA; Brossa PC; Giorda L; Pagni R; Aimo G
J Neurol Sci; 1999 Jan; 162(1):74-83. PubMed ID: 10064173
[TBL] [Abstract][Full Text] [Related]
10. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis.
Monzani F; Caraccio N; Meucci G; Lombardo F; Moscato G; Casolaro A; Ferdeghini M; Murri L; Ferrannini E
Eur J Endocrinol; 1999 Oct; 141(4):325-31. PubMed ID: 10526243
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration.
Caraccio N; Dardano A; Manfredonia F; Manca L; Pasquali L; Iudice A; Murri L; Ferrannini E; Monzani F
J Clin Endocrinol Metab; 2005 Jul; 90(7):4133-7. PubMed ID: 15811929
[TBL] [Abstract][Full Text] [Related]
12. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta 1b in the treatment of multiple sclerosis.
Río J; Montalban X
Expert Opin Pharmacother; 2005 Dec; 6(16):2877-86. PubMed ID: 16318438
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Baum K;
J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
16. [Current status of interferon beta-1b in multiple sclerosis therapy].
Hartung HP
Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
[TBL] [Abstract][Full Text] [Related]
17. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.
Durelli L; Ferrero B; Oggero A; Verdun E; Ghezzi A; Montanari E; Zaffaroni M;
Neurology; 2001 Oct; 57(8):1363-70. PubMed ID: 11673572
[TBL] [Abstract][Full Text] [Related]
18. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
20. Interferon treatment may trigger primary headaches in multiple sclerosis patients.
La Mantia L; D'Amico D; Rigamonti A; Mascoli N; Bussone G; Milanese C
Mult Scler; 2006 Aug; 12(4):476-80. PubMed ID: 16900761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
